Adam Young’s Post

CALQUENCE plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial. The recent results from the ECHO Phase III trial showed AstraZeneca’s CALQUENCE (acalabrutinib) in combination with bendamustine and rituximab demonstrated an improvement in progression-free survival (PFS) and showed a favourable trend in overall survival (OS) compared to standard-of-care chemoimmunotherapy (bendamustine plus rituximab) in previously untreated patients with mantle cell lymphoma (MCL).

🌍🎗 Each year, Lymphoma and Leukemia Awareness month is held in September and the 15th of the month is World Lymphoma Awareness Day. At Prospection, we are proud to be contributing to the fight against lymphoma and other common types of cancers by helping pharma clients gain valuable insights on the patient care journey using patient-centric intelligence. Through our extensive experience illuminating care’s impact on share, we helped to identify mantle cell lymphoma (MCL) patient treatment profiles for a large pharma client. These insights played a crucial role in guiding the client's decisions on launch planning, submission modeling, and medical communications planning. Learn more about Prospection’s impactful work that helped uplift care-and-share 👉 https://lnkd.in/gWhqiCFa #WorldLymphomaAwarenessDay #MCL #PatientCentricIntelligence #RWD

📣 Did you know? T-cell lymphomas, though less common than B-cell lymphomas, are a diverse group of diseases with unique clinical features and treatment considerations. They account for 15% of all non-Hodgkin lymphomas. 🧬💉 At SciTech Development, we're committed to advancing oncology treatments. Follow us to keep up with our #clinicaltrials with our groundbreaking science on #nanofenretinide, a promising drug for T-cell lymphomas. 💪🔬 Visit www.scitechsdp.com to learn more. #scitechSDP #scitechdevelopment #nanofenretinide #fenretinide #lymphoma #nonhodgkin #ST001

Now that we're moving from AAVD to nivo-AVD in Hodgkin's Lymphoma, do we need to give pegfilgrastim at all in these patients?  We know that patients with Hodgkin's lymphoma are highly unlikely to develop febrile neutropenia, and some studies have looked at not giving G-CSF no matter the dose with ABVD (https://lnkd.in/gHGpne4q).  AAVD is such a neutropenic regimen that we generally gave prophylactic pegfilgrastim, but now that nivo-AVD is becoming standard of care, we might want to hold off on pegfilgrastim.  About 5% of patients had febrile neutropenia in SWOG S1826, so we still want to give G-CSF if patients are neutropenic, but filgrastim is a reasonable option. Some studies have shown a short duration of filgrastim (2-4 days) would be effective in Hodgkin's lymphoma, and it saves patients the cost of pegfilgrastim. #hodgkinslymphoma #neulasta #opdivo https://lnkd.in/gDPChtTi

🔬 New research is helping to unravel the mystery of why many non-Hodgkin lymphoma patients develop resistance to treatment. Patients with B-cell lymphomas, which are most often classified as non-Hodgkin lymphoma (NHL), can frequently develop resistance to one of the most common forms of treatment: BTK inhibitors. BTK (Bruton tyrosine kinase) inhibitors work by slowing down the growth of cancerous B-cells in NHL. However many patients find that these drugs start to become ineffective after a few years of treatment, and their cancer starts growing again. Now, researchers from the University of Wisconsin-Madison have found that a single protein involved in energy production may be responsible for this treatment resistance. The scientists discovered this protein, called EGR1, becoming highly active in cancer cells during BTK inhibitor treatment – this is sort of like a backup generator kicking in after a building’s power goes out! With this in mind, scientists are now looking at how to reduce the levels of EGR1 in cancer cells, which would make them less able to rely on their backup generator! Clinical trials are already in the works to test this theory, and help patients with non-Hodgkin lymphoma avoid developing a resistance to BTK inhibitors. Read the original research here: https://bit.ly/3xjPzRp

I'm happy to share our latest preprint, now available on BioRxiv. Our work reveals that the IgG2 format of the anti-CD20 monoclonal antibody (mAb) rituximab (RTX-IgG2) significantly enhances the anti-tumor activity of other mAbs targeting B-cell lymphoma by boosting antibody-dependent cellular phagocytosis. This phagocytosis-enhancing effect of RTX-IgG2 is attributed to its ability to alter the 'don't-eat-me' CD47 signal on B-cell lymphoma cells. We hope that these findings will offer valuable insights for developing more effective treatments against B-cell lymphoma. Link to the preprint: https://lnkd.in/gSpnkagy

Bristol Myers Squibb is excited to announce that the #FDA has granted accelerated approval for #Breyanzi (lisocabtagene maraleucel; liso-cel), a #CARTcelltherapy, for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more prior lines of therapy. This approval, based on response rate and duration, represents a strategic milestone in the company's commitment to advancing cell therapy. #Breyanzi is now a Category 2A recommendation in the #NCCNGuidelines for third-line and subsequent therapy for relapsed/refractory FL, offering the potential for lasting remission in a one-time infusion. Breyanzi is a cornerstone of the cell therapy portfolio, providing a differentiated profile across a wide array of B-cell malignancies. #BristolMyersSquibb #Breyanzi #FDAApproval #CancerTreatment #CAR-T #FollicularLymphoma #CellTherapy Follow our page for more industry updates: https://lnkd.in/dGRWp6FD

🎗️ Unite for Lymphoma Awareness: Let's Make a Difference! 🌟 Today, on World Lymphoma Awareness Day, we come together to raise our voices and shine a spotlight on this important cause. 🌍 🌐 Theme of the Year: "Knowledge Empowers, Early Detection Saves Lives" – Together, we aim to spread knowledge about lymphoma and emphasize the critical role of early detection in improving outcomes. Join us in spreading awareness about lymphoma. Later in the day, we will share facts about lymphoma. Stay tuned. Let's share stories, facts, and hope. Together, we can make a difference and support those affected by lymphoma. 💪💙 Don't forget to visit www.utogenx.com for more information and resources on lymphoma awareness and prevention. #LymphomaAwarenessDay #FightLymphoma #CancerAwareness #WorldLymphomaAwarenessDay #LymphomaAwareness #KnowLymphoma #EarlyDetectionSavesLives #LymphomaSupport

Advances in bispecific antibodies and antibody-drug conjugates are revolutionizing treatment for Hodgkin, follicular, and diffuse large B-cell lymphoma. Check out this series of bite-sized programs to discover extensive clinical trial data on treatment options for lymphoma. Leading experts discuss strategies for individualizing frontline treatment for Hodgkin, follicular, and diffuse large B-cell lymphoma, review updates to NCCN guidelines for care, and break down the benefits of bispecific antibodies and antibody drug conjugates in lymphoma management. Optimize lymphoma care in your practice: https://bit.ly/45hMb4v

Did you know that BRUKINSA® (zanubrutinib) is currently FDA approved for: 1) mantle cell lymphoma, 2) Waldenström macroglobulinemia, 3) relapsed or refractory marginal zone lymphoma, and 4) Chronic lymphocytic leukemia or small lymphocytic lymphoma? NCODA has developed an educational video for each of the respective indications. Click the link below to view NCODA’s most recent video on zanubrutinib for relapsed or refractory marginal zone lymphoma. https://lnkd.in/gE3mK-Vj